ir.contravir.comContraVir Pharma @ContraVirPharma Twitter
ir.contravir.com Profile
Ir.contravir.com is a subdomain of contravir.com, which was created on 2013-05-16,making it 11 years ago.
Description：The latest Tweets from ContraVir Pharma @ContraVirPharma ContraVir is a biopharmaceutical company focused on the clinical development of TXL™ and CRV431 to treat Hep B Edison...
Discover ir.contravir.com website stats, rating, details and status online.Use our online tools to find owner and admin contact info. Find out where is server located.Read and write reviews or vote to improve it ranking. Check alliedvsaxis duplicates with related css, domain relations, most used words, social networks references. Go to regular site
ir.contravir.com Information
| HomePage size: 78.297 KB |
| Page Load Time: 0.851402 Seconds |
| Website IP Address: 23.203.217.146 |
ir.contravir.com Similar Website
| RoughneckHoops - Coach With A Purpose |
| Pharmacology Conferences | Pharmaceutical Conference | Pharma events 2024 | Drug Conference | Pharma |
| Future Pharma 2020 | Pharma Marketing & Sales Conference |
| Twitter Fiction on Thaumatrope: The Twitter Fiction E-zine of Science Fiction, Fantasy, & Horror |
| big pharma news headlines - big pharma News |
| Twitter for Business | Twitter tips, tools, and best practices |
| Pharma Industry News - Pharma Industry News |
| Twitter Feed : feed your blog to twitter |
| Jeff Reifman's Twitter Archive - Tweets from @reifman Jeff Reifman's Twitter Archive |
| Nova Pharma Academy – Nova Pharma Learning |
ir.contravir.com Httpheader
| Accept-Ranges: bytes |
| Content-Encoding: gzip |
| Content-Language: en |
| Content-Security-Policy: report-uri //report-csp-violation |
| Content-Type: text/html; charset=UTF-8 |
| device: desktop |
| ETag: "1580716617" |
| From-Origin: same |
| Last-Modified: Mon, 03 Feb 2020 07:56:57 GMT |
| Link: http://ir.contravir.com/; rel="shortlink", http://ir.contravir.com/; rel="canonical", http://ir.contravir.com/investor-relations; rel="alternate"; hreflang="en", http://ir.contravir.com/investor-relations; rel="revision" |
| Server: nginx |
| X-Age: 0 |
| X-Content-Security-Policy: report-uri //report-csp-violation |
| X-Content-Type-Options: nosniff |
| X-Drupal-Dynamic-Cache: UNCACHEABLE |
| X-Frame-Options: SAMEORIGIN |
| X-Generator: Drupal 8 (https://www.drupal.org) |
| X-Request-ID: v-c012146e-465a-11ea-a093-9f0562e48de9 |
| X-UA-Compatible: IE=edge |
| X-WebKit-CSP: report-uri //report-csp-violation |
| X-XSS-Protection: 1; mode=block |
| Content-Length: 14029 |
| X-EdgeConnect-MidMile-RTT: 40 |
| X-EdgeConnect-Origin-MEX-Latency: 631 |
| Cache-Control: public, max-age=0, s-maxage=1800 |
| Expires: Mon, 03 Feb 2020 07:56:57 GMT |
| Date: Mon, 03 Feb 2020 07:56:57 GMT |
| Connection: keep-alive |
| Vary: Accept-Encoding |
| Set-Cookie: SimpleSAMLSessionID=ac973e316de9bca7b3cb97cd8429ce69; path=/; secure; HttpOnly, DrupalVisitorMobile=0; path=/ |
ir.contravir.com Meta Info
| charset="utf-8"/ |
| content="Investor Relations | Hepion Pharmaceuticals, Inc." name="title"/ |
| content="Hepion Pharmaceuticals, Inc." property="og:site_name"/ |
| content="website" property="og:type"/ |
| content="no-referrer" name="referrer"/ |
| content="Drupal 8 (https://www.drupal.org)" name="Generator"/ |
| content="width" name="MobileOptimized"/ |
| content="true" name="HandheldFriendly"/ |
| content="width=device-width, initial-scale=1.0" name="viewport"/ |
ir.contravir.com Ip Information
| Ip Country: United States |
| City Name: Santa Clara |
| Latitude: 37.353 |
| Longitude: -121.9543 |
ir.contravir.com Html To Plain Text
Company Overview Executive Team Board of Directors Scientific Advisory Board Partnering Liver Disease Overview Non-Alcoholic SteatoHepatitis (NASH) Hepatocellular Carcinoma (HCC) Viral Hepatitis Pipeline Drug Candidates CRV431 Therapeutic Strategy Clinical Trials News Press Releases Hepion in the News Presentations Publications Investors Overview News Releases Events Presentation Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Financials & Filings SEC Filings Fundamentals Annual Reports & Proxy Statements Corporate Governance Documents & Charters Management Team Board of Directors Committee Composition Investor Resources Investor FAQs Email Alerts Contact IR RSS Feeds Search Investors Contact Contact Us Careers Press enter to begin your search Main navigation Home About Company Overview Executive Team Board of Directors Scientific Advisory Board Partnering Liver Disease Overview Non-Alcoholic SteatoHepatitis (NASH) Hepatocellular Carcinoma (HCC) Viral Hepatitis Pipeline Drug Candidates CRV431 Therapeutic Strategy Clinical Trials News Press Releases Hepion in the News Presentations Publications Investors Overview News Releases Events Presentation Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Financials & Filings SEC Filings Fundamentals Annual Reports & Proxy Statements Corporate Governance Documents & Charters Management Team Board of Directors Committee Composition Investor Resources Investor FAQs Email Alerts Contact IR RSS Feeds Search Investors Contact Contact Us Careers Investor Relations Hepion is a biopharmaceutical company focused on the development and commercialization of targeted therapies for liver disease arising from chronic hepatitis B, C and D virus (HBV, HVC, HDV) and non-alcoholic steatohepatitis (NASH). Price: Investor Relations Corporate Profile Hepion Pharmaceuticals is a clinical stage biopharmaceutical company focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection (HBV, HCV, HDV). The Company’s lead drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Preclinical studies also have demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms. These diverse therapeutic activities result from CRV431’s potent inhibition of cyclophilin enzymes, which are involved in many disease processes. Currently in clinical phase development, CRV431 shows potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. For more information, please visit www.hepionpharma.com . News Releases Summary Toggle Summary Toggle Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference Summary Toggle September 4, 2019 Summary Toggle EDISON, N.J. , Sept. 04, 2019 (GLOBE NEWSWIRE)Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH”) and chronic viral infection, today Summary Toggle Summary Toggle Summary Toggle Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements Summary Toggle September 3, 2019 Summary Toggle EDISON, N.J. , Sept. 03, 2019 (GLOBE NEWSWIRE)Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (NASH”) and chronic viral infection, today Summary Toggle Summary Toggle Summary Toggle Hepion Pharmaceuticals Announces Dosing of First HBV Patient in 28-Day Study of CRV431 Summary Toggle August 14, 2019 Summary Toggle Study Represents the Third and Final Stage of CRV431’s Streamlined Early Clinical Program EDISON, N.J. , Aug. 14, 2019 (GLOBE NEWSWIRE)Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease Summary Toggle Latest Events Hepion Pharmaceuticals to Present at the H. C. Wainwright 21st Annual Global Investment Conference Sep 10, 2019 at 4:15 PM EDT Click here for webcast ContraVir Pharmaceuticals to Present at the 2019 ThinkEquity Conference May 2, 2019 at 1:30 PM EDT Listen to webcast Latest Form 10-K Mar 14, 2019 View HTML 0001104659-19-014652.pdf 0001104659-19-014652.rtf 0001104659-19-014652.xls EX-101.INS - XBRL INSTANCE DOCUMENT Latest Form 10-Q Nov 14, 2019 View HTML 0001104659-19-064342.pdf 0001104659-19-064342.rtf 0001104659-19-064342.xls EX-101.INS - XBRL INSTANCE DOCUMENT Latest Proxy Statement Apr 02, 2019 View HTML 0001104659-19-019408.pdf 0001104659-19-019408.rtf 0001104659-19-019408.xls Contact IR Stephen Kilmer Investor Relations Phone: 646.274.3580 Email: skilmer@contravir.com Get Important News and Updates by Email Subscribe © 2020 Hepion Pharmaceuticals, Inc. | Disclaimer & Terms of...
ir.contravir.com Whois
Domain Name: CONTRAVIR.COM Registry Domain ID: 1801616821_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.godaddy.com Registrar URL: http://www.godaddy.com Updated Date: 2024-05-10T13:45:28Z Creation Date: 2013-05-16T02:46:43Z Registry Expiry Date: 2025-05-16T02:46:43Z Registrar: GoDaddy.com, LLC Registrar IANA ID: 146 Registrar Abuse Contact Email: abuse@godaddy.com Registrar Abuse Contact Phone: 480-624-2505 Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: NS01.DOMAINCONTROL.COM Name Server: NS02.DOMAINCONTROL.COM DNSSEC: unsigned >>> Last update of whois database: 2024-05-17T19:23:13Z <<<